70 results about "Primary cancer" patented technology

The present invention provides methods of preventing and / or treating cancers (including tumors). In one preferred embodiment, the invention is practiced to induce regression of an existing cancer or tumor and / or to prevent metastasis and / or to prevent growth of metastatic nodules. In other preferred embodiments, the invention may be used as a prophylaxis to prevent the development of primary cancers through a childhood or adult vaccination program against specific tumor antigens for cancers with high incidences. In an alternate preferred embodiment, the present invention provides methods of establishing an immune response against a universal artificial tumor antigen through a childhood or adult vaccine program, thus providing a long-term immune response that can be utilized at any point to treat any cancer which develops later in life. The present invention also provides cancer and tumor cells stably expressing an artificial antigen, preferably an artificial cell-surface antigen.

The invention discloses a method of identifying a gene associated with stage III primary cancer or lymph node metastasis. The genes so identified include CAV1, CST3, LIMK1, MMP2, MMP15, VEGF, ETV4, MMP9, PIK3C2B, and SERPIN1. Also disclosed are methods for diagnosis, prognosis, and treatment of cancer. The invention further discloses compositions for preventing and treating diseases.

Among the genes identified, in a comparison of the global gene expression profile of metastatic colorectal cancer to that of primary cancers, benign colorectal tumors, and normal colorectal epithelium, the PRL-3 protein tyrosine phosphatase gene was of particular interest. It was expressed at high levels in each of 18 cancer metastases studied but at lower levels in non-metastatic tumors and normal colorectal epithelium. In three of twelve metastases examined, multiple copies of the PRL-3 gene were found within a small amplicon located at chromosome 8q24.3. These data suggest that the PRL-3 gene is important for colorectal cancer metastasis and provides a new therapeutic target for these intractable lesions.

The present invention provides methods of treating cancer, the methods generally involving combination therapy. The methods are useful as primary cancer therapy, or as adjuvant therapy. The present invention further provides diagnostic methods for determining the responsiveness of a given tumor to treatment with a combination therapy.

Methods for assessing stage of cancer in a subject are provided, comprising administering a macrophage imaging agent to the subject, making a magnetic resonance image of regions of the subject's body at cancer risk, and using the image to assess macrophage density and displacement associated with any primary cancer or metastatic cancer in the subject, such density and displacement being indicative of neoplasia. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle and in particular embodiments, the macrophage imaging agent has a blood half-life sufficient to permit microphage trapping throughout the regions at cancer risk. Additional embodiments provide methods for assessing efficacy of an anticancer treatment in a subject, methods for determining frequency of follow-up MEMRI evaluation in a subject, methods for determining metastatic potential of cancer foci in a subject, and methods for determining prognosis of cancer in a subject. Methods for directing site of biopsy in a subject by performing a whole body MEMRI evaluation of the subject to identify macrophage density at a tumor site of interest and assessing the macrophage density to identify the site of biopsy in the subject, macrophage density being an indicator of tumor growth are also provided, in addition to methods for providing individualized cancer treatment to a subject in need thereof using whole body MEMRI evaluation.

The invention discloses three gene groups for transferring and typing prognostic numerator to breast cancer, a gene chip, an unsupervised clustering map from a gene expression profile and a method for transferring and typing prognostic numerator to breast cancer patients. The invention is characterized in that: the gene chip is point-sampled and prepared by specific cDNA or oligonucleotide of the gene groups with an lattice form on the surface of the supports, and is used for transferring and typing prognostic numerator to breast cancer; the cDNA or amplified products of primary cancer tissue specimens based on breast cancer patients are fluorescence-marked and then crossbred with the gene chip for transferring and typing prognostic numerator to breast cancer, and then the gene expression profile is obtained, and the unsupervised clustering map for transferring and typing prognostic numerator to patients comes from the gene expression profile; the method makes use of the gene chip and the gene expression profile for transferring and typing prognostic numerator to breast cancer.

Compositions and methods for preventing or treating primary cancer cell growth and tumor metastasis, as well as stimulation of hematopoiesis are described and claimed. The present invention also relates to methods of treating cancer and uteroglobin receptor-related conditions by targeting a uteroglobin receptor with recombinant human uteroglobin (rhUG). Also disclosed and claimed are methods of purifying a uteroglobin receptor and methods of using such receptor(s) to identify uteroglobin structural analogs and UG-receptor ligands.

Robust classification methods analyze magnetic resonance spectroscopy (MRS) data (spectra) of fine needle aspirates taken from breast tumors. The resultant data when compared with the histopathology and clinical criteria provide computerized classification-based diagnosis and prognosis with a very high degree of accuracy and reliability. Diagnostic correlation performed between the spectra and standard synoptic pathology findings contain detail regarding the pathology (malignant versus benign), vascular invasion by the primary cancer and lymph node involvement of the excised axillary lymph nodes. The classification strategy consisted of three stages: pre-processing of MR magnitude spectra to identify optimal spectral regions, cross-validated Linear Discriminant Analysis, and classification aggregation via Computerised Consensus Diagnosis. Malignant tissue was distinguished from benign lesions with an overall accuracy of 93%. From the same spectrum, lymph node involvement was predicted with an accuracy of 95% and tumor vascularisation with an overall accuracy of 92%.

The invention relates to a circulating tumor cell mouse model and a construction method and application thereof. The method includes the following steps of 1, subcutaneous transplantation, wherein a primary tumor tissue sample is transplanted into the body of an immunodeficient mouse to construct a primary cancer heterotransplantation model PDX; 2, collection of circulating tumor cells, wherein the circulating tumor cells in peripheral blood in the primary cancer heterotransplantation model obtained in the step 1 are collected; 3, renal sac membrane transplantation, wherein the circulating tumor cells collected in the step 2 are transplanted into the renal sac membrane of the immunodeficient mouse, and then the circulating tumor cell mouse model is successfully constructed. According to the method, the mode of transplantation with two or more times of passages is adopted, the CTCs in the primary cancer heterotransplantation model are transplanted into the body of the immunodeficient mouse through renal sac membrane, and the circulating tumor cell mouse model is obtained; the circulating tumor cell mouse model can be applied to research on the in-vivo metastasis mechanism and proliferation condition of CTCs.

Provided herein is a method for diagnosing / prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL−1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

A method and composition for of treating cancer, and in particular, for arresting the progression of a solid or primary cancer to a more invasive, metastatic state, are disclosed. The composition includes a substantially uncharged antisense compound (i) having a nuclease-resistant backbone, (ii) capable of uptake by target cancer cells in the subject, (iii) containing between 10-40 nucleotide bases, and (iv) having a base sequence effective to hybridize to a region of processed or preprocessed human SNAIL RNA transcript. The compound, when administered to the subject, is effective to form within target cancer cells in the subject, a base-paired heteroduplex structure composed of human SNAIL RNA transcript and the oligonucleotide compound, where this structure is characterized by a Tm of dissociation of at least 45° C. The compound is administered in an amount sufficient to inhibit SNAIL expression in target cancer cells, thereby to inhibit the progression of the patient's cancer to a more invasive, metastatic state. Also disclosed are methods for preventing the transdifferentiation of peritoneal mesothelial cells and failure of ultrafiltration in a patient undergoing peritoneal dialysis, by including the compound in the patient dialysis fluid.

The invention discloses a method for utilizing a malignant pleural effusion for separately culturing primary cancer cells. The method comprises the steps of putting a pleural effusion sample into a sample collecting liquid, and centrifuging to remove a supernatant; adding a red blood cell lysis buffer for removing a red blood cell, adding a PBS buffer solution for washing the cells, and centrifuging to remove a supernatant; using a KL culture medium for resuspending a cell precipitate, inoculating in a culture flask, and culturing in a culture box. When the cells are proliferated to more than85 percent of abundance, the cells are washed through the PBS buffer solution, pancreatin-EDTA is digested, and a stop buffer neutralizes digestion reaction; the cells are centrifugally collected, areresuspended through the KL culture medium, and inoculated in the cell flask according to the proportion so as to be subcultured. The primary cancer cells of the pleural effusion obtained by separatedculture through the method provided by the invention can be applied to related research of physiology, pharmacy, new drug research and development and the like, exploration of pathogenesis of relateddiseases of a lung cancer, detection of drug sensitivity of different drugs, screening of anti-cancer drugs, new drug research and development, and establishment of a personalized treatment program aiming at a patient.

A method of producing a cell mass by three-dimensional culture of primary cancer cells having proliferative ability and properties of handleability, versatility, and high-throughput performance, in which a tumor tissue is used as a starting material, proliferation of cells such as fibroblasts other than cancer cells is inhibited, and the cell mass includes primary cancer cells as a main component. The object is achieved by providing a method of producing a cell mass by three-dimensional culture of primary cancer cells using a tumor tissue, including: a three-dimensional culture step of culturing cells obtained from the tumor tissue in a medium containing a 5% v / v or less extracellular matrix on a substantially low-adhesive cell culture substrate.

The invention discloses a relative transferring function of kinesin family member KIF1B, a landmark application thereof in predicting tumor patient prognosis and an application method thereof, belonging to the technical field of tumor molecular biology. The invention discloses a relative transferring function of kinesin family member KIF1B, a landmark application of KIF1B expression level in predicting tumor patient prognosis and a detection and application method based on the KIF1B expression level in predicting tumor patient prognosis. In the method, real-time quantitative RT-PCR is carried out to detect the method for KIF1B mRNA expression level; quantitative PCR amplification comprises relative quantitative PCR amplification and absolute quantitative PCR amplification; the KIF1B expression level detection can also adopt a molecular hybridization method to detect the KIF1B mRNA expression level; an immunostaining method and / or immunoblotting method can be adopted to detect the KIF1B protein expression level; a critical value for prognosis judgment is determined according to the KIF1B gene or protein expression level in the primary cancer tissues of recurrent and metastatic positive cases and recurrent and metastatic negative cases of tumor patients; and the patient the critical value of whom is higher than the threshold value has favorable prognosis, and the patient the critical value of whom is lower than the threshold value has poor prognosis.

The invention comprises the administration of an amount of honokiol (HNK) and Modified Citrus Pectin (MCP) or similar pectin or alginate in amounts synergistic to inhibit cancer. The inhibition can be of the formation of cancer, the progression of a cancer already formed, or the transformation of a primary cancer to a metastatic one. HNK and MCP appear to be synergistic across their effective ranges, and the synergy may be due in part to the binding of galectin-3 on the surface of tumor cells by MCP, which better presents the cell for the cytotoxic effects of HNK. Compositions of matter which combine the two agents, HNK and MCP, in synergistic amounts intended for daily administration are also contemplated. The administration of MCP and HNK may be combined with the administration of conventional anti-cancer therapeutics.

Gene expression patterns were analyzed that identified multiple genes associated with radiation enhanced colon carcinogenesis. Some of the genes modulated by radiation exposure may be involved in up-regulating the Wnt / β-catenin signaling pathway and promote colon carcinogenesis. Consumption of a fish oil / pectin diet caused a general down-regulation of genes encoding proteins involved in cell adhesion and receptor activity, which may be involved in down-regulating the Wnt / β-catenin signaling pathway. The data suggest that dietary fish oil / pectin may be an effective countermeasure against radiation-induced colon carcinogenesis. In accordance with this, gene expression profiles can be monitored to reduce the risk of radiation induced carcinogenesis in high risk personnel (i.e., for example, astronauts) before, during, and / or after radiation exposure (i.e., for example, spaceflight), and / or to detect radiation-induced carcinogenesis so that an appropriate countermeasure administration can be implemented. The techniques are also targeted at non-invasively monitoring cancer patients after the primary cancer has been resected to determine if / when a secondary tumor develops.

The invention discloses a medicine for treating liver cancer. The medicine comprises the following Chinese herbal medicines of virgate wormwood herb, szechwan chinaberry fruit, cassia seed, tuber fleeceflower root, leech, ginseng, hawthorn fruit and the like in a weight ratio. According to the medicine, the effective rate of treating primary cancer liver in moderate and advanced stages is 76.2 percent, and tumors are stable and difficultly relapse after treatment. Experiments on hearts, livers, spleens, lungs and kidneys of animals are performed within the range of treatment dose, and the toxic or side effects are not obvious.

The invention provides a preparation method of anti-tumor microparticles. The preparation method includes the following steps: 1) taking in-vitro tumor cells, performing primary tumor cell culture soas to obtain primary tumor cells; 2) irradiating the primary cancer cells and culture solution obtained in the step 1) with X rays, and collecting the supernatant after radiotherapy so as to obtain amixture of the desired microparticles and apoptotic tumor cell fragments; and 3) performing gradient centrifugation on the mixture obtained in the step 2) so as to obtain the anti-tumor microparticles. The invention also provides an anti-tumor microparticle drug, and the drug is obtained through purification and concentration of the anti-tumor microparticles. The anti-tumor microparticles which are prepared by using the preparation method of the anti-tumor microparticles can be applied to preparation of anti-tumor drugs, and the technical problem of no applicability of conventional radiotherapy can be solved.

Among the genes identified, in a comparison of the global gene expression profile of metastatic colorectal cancer to that of primary cancers, benign colorectal tumors, and normal colorectal epithelium, the PRL-3 protein tyrosine phosphatase gene was of particular interest. It was expressed at high levels in each of 18 cancer metastases studied but at lower levels in non-metastatic tumors and normal colorectal epithelium. In three of twelve metastases examined, multiple copies of the PRL-3 gene were found within a small amplicon located at chromosome 8q24.3. These data suggest that the PRL-3 gene is important for colorectal cancer metastasis and provides a new therapeutic target for these intractable lesions.

The invention discloses a stomach cancer metastasis therapeutic device. The device comprises a casing, a motor, a vibration friction head, a spring, a speed-control switch and stype. In the stage of preventing the occurrence of stomach cancer metastasis after operation, an externally used chemotherapeutic drug is applied to a primary cancer focus and peripheral and remote end parts where cancer cells are easy to spread, and the device is adopted for the treatment focusing on medicinal massage for recovering functions and taking killing the cancer cells as a supplement, and prevents the occurrence of stomach cancer metastasis. In the stage of occurrence of stomach cancer metastasis, an externally used chemotherapeutic drug is applied to the primary cancer focus, a metastasis focus part, parts around the focus, and corresponding parts on the back, main treatment performing medicinal massage, transdermal drug delivery and chemotherapy controls stomach cancer metastasis is performed to eliminate cancer metastasis, and an externally used supporting drug is applied to other parts with functions being decreased, so as to perform medicinal massage and function recovery auxiliary treatment. In the stage of stomach cancer metastasis and death occurrence, the main treatment combining full-body supporting drug massage and full-body horizontal extensional movements for recovering a full-body function is performed, and meanwhile the auxiliary treatment of small-dose intravenous chemotherapy for killing the cancer cells is performed, so as to eliminate death occurrence factors.

The invention provides a separation preparation method for human primary cancer cells. According to the separation preparation method, the culture process is divided into two periods, culture is carried out with culture mediums with fetal calf serum of different concentrations respectively, the concentrations of the fetal calf serum in the culture mediums are increased gradually, then the adaptability and the activity of primary cancer cells are improved gradually, relatively rapid cell proliferation and relatively high yield are achieved, and meanwhile good hereditary stability is achieved; due to addition of sodium pyruvate, MaxCitro, Y-27632 and griseofulvin, bacterial and fungal infection can be prevented, cell proliferation can be promoted, and cell differentiation can be inhibited; and due to addition of a plant source recombinant human serum albumin in a cryoprotectant, a part of fetal calf serum can be replaced, the use amount of the fetal calf serum can be reduced, and thus the cost can be lowered on premise that the effect is not affected.

The present invention relates to methods for the prognosis of the progression of cancer in a patient, and more particularly methods for the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a cancer, in particular with a breast cancer, a lung cancer or other primary cancer, said methods comprising the step of detecting a higher expression level of FERMT1 gene in a tumour sample compared to a control reference values. The invention further relates to inhibitors of FERMT1 expression and their uses in the treatment of cancer or metastasis.

The present invention relates to a vaccine composed of at least one immune stimulant and radiofrequency waves using capacitive coupling and to a method, especially an in-situ and in vivo vaccination method for treatment of primary cancer and its metastases even in disseminated cell-states, which cannot be detected by presently available imaging methods or for prevention of relapse of the cancer disease, and especially for enabling and supporting the patient's own immune system to recognize and kill the cancer cells and to build up a memory to prevent relapse of a cancer disease.

Provided herein is a method for diagnosing / prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL-1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.

The invention discloses a cell culture layer which is prepared by the following methods: culturing BALB3T3 cells by adopting a DMEM culture medium, performing cell adherent culture until 70-80 percent of a culture bottle is full, and irradiating; performing X-ray irradiation by taking 3000cGy as a radiation dose; culturing by using an improved F culture medium after irradiation; culturing for 8 hours, and obtaining the culture, namely the cell culture layer. The cell culture layer can be used for culturing human primary cancer cells or cancer stem cells. The invention also discloses improvement of cell types of the cell culture layer as well as a preparation method of the cell culture layer. Compared with J2 cells, the 3T3 cells for preparing the culture layer are easily obtained, and the cell concentration and state can be easily controlled in the culture process. When the cell culture layer is used for culturing the human primary cancer cells or cancer stem cells, growth of the primary cancer cells can be well promoted, and human cancer stem cells in a higher ratio are obtained (the number of CD44 positive cells is improved by about 80 percent).

The invention discloses a focus detection method, device and equipment and a storage medium, and the method comprises the steps: obtaining a first image comprising a plurality of sampling slices, wherein the first image is a three-dimensional image comprising an X-axis dimension, a Y-axis dimension and a Z-axis dimension; performing feature extraction on the first image to generate a first featuremap containing features and positions of lesions; wherein the first feature map comprises three-dimensional features of an X-axis dimension, a Y-axis dimension and a Z-axis dimension; performing dimension reduction processing on features contained in the first feature map to generate a second feature map; wherein the second feature map comprises two-dimensional features of an X-axis dimension anda Y-axis dimension; and detecting the features of the second feature map to obtain the position of each lesion in the second feature map and the confidence coefficient corresponding to the position.By adopting the method and the device, the focus conditions of a plurality of parts in the body of the patient can be accurately detected, and primary cancer assessment of the whole body range of thepatient is realized.

Compositions and methods for preventing or treating primary cancer cell growth and tumor metastasis, as well as stimulation of hematopoiesis are described and claimed. The present invention also relates to methods of treating cancer and uteroglobin receptor-related conditions by targeting a uteroglobin receptor with recombinant human uteroglobin (rhUG). Also disclosed and claimed are methods of purifying a uteroglobin receptor and methods of using such receptor(s) to identify uteroglobin structural analogs and UG-receptor ligands.